Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
‘Everybody hates you now’: Trump reportedly takes aim at Netanyahu in explosive call Dementia Could Begin in Your Legs, Warns Leading Neurologist Australia hits new population milestone Stolen car ...
The soaring use of weight loss jabs the UK is hitting supermarket sales as the so-called “small appetites” economy grows. Research by retail data firm Worldpanel by Numerator shows that weight loss ...